The role of genetic testing in accurate diagnosis of X-linked sideroblastic anemia: novel ALAS2 mutations and the impact of X-chromosome inactivation
Por:
Jové-Solavera D, Rámila M, Ferrer-Cortés X, Olivella M, Venturi V, Morado M, Hernández-Rodríguez I, Khan A, Pérez-Montero S, Tornador C, Germing U, Gattermann N and Sanchez M
Publicada:
7 abr 2025
Ahead of Print:
7 abr 2025
Resumen:
X-linked sideroblastic anemia (XLSA) is a hereditary disorder affecting heme biosynthesis, caused by mutations in the ALAS2 gene, which encodes the erythroid-specific enzyme 5-aminolevulinate synthase. This enzyme, which requires pyridoxal 5'-phosphate (PLP) as a cofactor, catalyzes the first and rate-limiting step of heme synthesis in erythroid cells. XLSA is characterized by hypochromic microcytic anemia and ring sideroblasts in bone marrow, with most patients showing variable degrees of response to pyridoxine supplementation; however, female carriers of ALAS2 mutations often present a distinct clinical phenotype. A comprehensive review of the literature reveals over 100 distinct ALAS2 mutations linked to XLSA in more than 240 families. Here, we report seven new patients (four female cases) initially diagnosed with various conditions, later confirmed to have X-linked Sideroblastic Anemia due to ALAS2 mutations through genetic analysis. Among these, five represent novel ALAS2 mutations, including the first ever reported stop-loss mutation in ALAS2 associated with XLSA rather than X-linked dominant protoporphyria (XLDPP). Computational modelling of six reported cases revealed that four mutations significantly impact protein structure, conformation and cofactor interaction, consistent with our enzymatic assays demonstrating reduced ALAS2 activity. Furthermore, X-chromosome studies in female probands revealed a pronounced skewing of X-chromosome, which may provide an explanation for their distinct clinical manifestations in females.
Filiaciones:
Jové-Solavera D:
Iron Metabolism: Regulation and Diseases, Department of Biomedical Sciences, Universitat Internacional de Catalunya (UIC), 08195, Sant Cugat del Vallès, Spain
Rámila M:
Iron Metabolism: Regulation and Diseases, Department of Biomedical Sciences, Universitat Internacional de Catalunya (UIC), 08195, Sant Cugat del Vallès, Spain
Ferrer-Cortés X:
Iron Metabolism: Regulation and Diseases, Department of Biomedical Sciences, Universitat Internacional de Catalunya (UIC), 08195, Sant Cugat del Vallès, Spain
BloodGenetics S.L. Diagnostics in Inherited Blood Diseases, 08950, Esplugues de Llobregat, Spain
Olivella M:
Biosciences Department, Faculty of Sciences and Technology, University of Vic - Central University of Catalonia, Vic, Spain
Venturi V:
Iron Metabolism: Regulation and Diseases, Department of Biomedical Sciences, Universitat Internacional de Catalunya (UIC), 08195, Sant Cugat del Vallès, Spain
Morado M:
Service of Hematology, Hospital La Paz, 28046, Madrid, Spain
:
Hematology Department, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Badalona, Barcelona, Spain
Khan A:
M.A.G.I.C. (Metabolics and Genetics in Canada), Calgary, AB, Canada
Pérez-Montero S:
BloodGenetics S.L. Diagnostics in Inherited Blood Diseases, 08950, Esplugues de Llobregat, Spain
Tornador C:
BloodGenetics S.L. Diagnostics in Inherited Blood Diseases, 08950, Esplugues de Llobregat, Spain
Germing U:
Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
Gattermann N:
Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
Sanchez M:
Iron Metabolism: Regulation and Diseases, Department of Biomedical Sciences, Universitat Internacional de Catalunya (UIC), 08195, Sant Cugat del Vallès, Spain
BloodGenetics S.L. Diagnostics in Inherited Blood Diseases, 08950, Esplugues de Llobregat, Spain
Green Submitted, gold
|